# Adoptive Transfer of pp65-specific T Cells for the Treatment of Refractory Cytomegalovirus (CMV) Infection

> **NCT02346617** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Yae-Jean Kim**

## Conditions studied

- Cytomegalovirus Infections

## Interventions

- **BIOLOGICAL:** IFN-γ positive selected T-cells

## Key facts

- **NCT ID:** NCT02346617
- **Lead sponsor:** Yae-Jean Kim
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-01-01
- **Primary completion:** 2023-12-01
- **Final completion:** 2024-12-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to the KoreaFDA issue
- **Last updated:** 2020-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02346617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02346617, "Adoptive Transfer of pp65-specific T Cells for the Treatment of Refractory Cytomegalovirus (CMV) Infection". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02346617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*